153 related articles for article (PubMed ID: 37751203)
1. Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
Su CC; Wu JT; Choi E; Myall NJ; Neal JW; Kurian AW; Stehr H; Wood D; Henry SM; Backhus LM; Leung AN; Wakelee HA; Han SS
JAMA Netw Open; 2023 Sep; 6(9):e2335813. PubMed ID: 37751203
[TBL] [Abstract][Full Text] [Related]
2. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
Moore S; Leung B; Wu J; Ho C
Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.
Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka S; Bebb DG; Cheung WY
Am J Clin Oncol; 2019 Jan; 42(1):75-81. PubMed ID: 30211724
[TBL] [Abstract][Full Text] [Related]
4. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
6. Presentation and outcomes of KRAS
Esfahanian N; Chan SWS; Zhan LJ; Brown MC; Khan K; Lee J; Balaratnam K; Yan E; Parker J; Garcia-Pardo M; Barghout SH; Eng L; Bradbury PA; Shepherd FA; Leighl NB; Sacher AG; Snow S; Juergens R; Liu G
Cancer Treat Res Commun; 2023; 37():100774. PubMed ID: 37979334
[TBL] [Abstract][Full Text] [Related]
7. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
8. Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial.
Potter AL; Costantino CL; Suliman RA; Haridas CS; Senthil P; Kumar A; Mayne NR; Panda N; Martin LW; Yang CJ
Ann Thorac Surg; 2023 Oct; 116(4):684-692. PubMed ID: 37356517
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
10. Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy.
Friedes C; Mai N; Fu W; Hu C; Han P; Marrone KA; Voong KR; Hales RK
Lung Cancer; 2020 Jul; 145():119-125. PubMed ID: 32434118
[TBL] [Abstract][Full Text] [Related]
11. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Oh BC; Cho AR; Nam JH; Yang SY; Kim MJ; Kwon SH; Lee EK
BMC Cancer; 2023 May; 23(1):482. PubMed ID: 37248452
[TBL] [Abstract][Full Text] [Related]
12. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
Ramagopalan SV; Popat S; Gupta A; Boyne DJ; Lockhart A; Hsu G; O'Sullivan DE; Inskip J; Ray J; Cheung WY; Griesinger F; Subbiah V
JAMA Netw Open; 2022 Nov; 5(11):e2239874. PubMed ID: 36326765
[TBL] [Abstract][Full Text] [Related]
13. Surgical Outcomes in Non-Small Cell Lung Cancer with Distant Metastasis: The Prognostic Significance of Delayed Metastasis Diagnosis.
Park S; Choe J; Lee SM; Choi S; Kim MJ; Chae EJ; Seo JB
Ann Surg Oncol; 2024 May; 31(5):3448-3458. PubMed ID: 38386197
[TBL] [Abstract][Full Text] [Related]
14. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
15. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.
Heiden BT; Eaton DB; Engelhardt KE; Chang SH; Yan Y; Patel MR; Kreisel D; Nava RG; Meyers BF; Kozower BD; Puri V
JAMA Netw Open; 2021 May; 4(5):e2111613. PubMed ID: 34042991
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Pattern Discriminates Survival Benefit of Type of Surgery in Patients With
Li K; Zhou C; Yu Y; Niu L; Zhang W; Wang B; He J; Ge G
Front Surg; 2021; 8():696628. PubMed ID: 34805256
[No Abstract] [Full Text] [Related]
19. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
20. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
